- Home
- COGT vs IMTX Comparison
COGT vs IMTX Comparison
Compare COGT & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- IMTX
- Stock Information
- Founded
- COGT 2014
- IMTX N/A
- Country
- COGT United States
- IMTX Germany
- Employees
- COGT N/A
- IMTX N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COGT Health Care
- IMTX Health Care
- Exchange
- COGT Nasdaq
- IMTX Nasdaq
- Market Cap
- COGT 900.3M
- IMTX 954.2M
- IPO Year
- COGT 2018
- IMTX N/A
- Fundamental
- Price
- COGT $7.90
- IMTX $7.07
- Analyst Decision
- COGT Buy
- IMTX Strong Buy
- Analyst Count
- COGT 6
- IMTX 4
- Target Price
- COGT $14.20
- IMTX $16.67
- AVG Volume (30 Days)
- COGT 1.7M
- IMTX 522.7K
- Earning Date
- COGT 11-12-2024
- IMTX 11-18-2024
- Dividend Yield
- COGT N/A
- IMTX N/A
- EPS Growth
- COGT N/A
- IMTX N/A
- EPS
- COGT N/A
- IMTX N/A
- Revenue
- COGT N/A
- IMTX $128,824,447.00
- Revenue This Year
- COGT N/A
- IMTX $90.79
- Revenue Next Year
- COGT N/A
- IMTX N/A
- P/E Ratio
- COGT N/A
- IMTX N/A
- Revenue Growth
- COGT N/A
- IMTX 52.53
- 52 Week Low
- COGT $4.28
- IMTX $6.99
- 52 Week High
- COGT $12.61
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- COGT 32.81
- IMTX 27.93
- Support Level
- COGT $7.94
- IMTX $6.99
- Resistance Level
- COGT $8.56
- IMTX $7.40
- Average True Range (ATR)
- COGT 0.60
- IMTX 0.30
- MACD
- COGT -0.06
- IMTX -0.00
- Stochastic Oscillator
- COGT 9.60
- IMTX 10.46
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.